Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21363536 | 0.91 | TRPA1 (0.44) | TRPA1SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL25165800 | 0.82 | TRPA1 (0.48) | TRPA1SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL22477724 | 0.80 | TRPA1 (0.46) | TRPA1SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL21363370 | 0.76 | TRPA1 (0.42) | TRPA1SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL21363642 | 0.74 | CYP2D6 (0.51) | SMN1; SMN2LMNAHTTRAB9ACYP2C19 | |
| SCHEMBL21363508 | 0.74 | TRPA1 (0.39) | TRPA1SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL21393579 | 0.72 | LMNA (0.44) | TRPA1SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL21363377 | 0.70 | TRPA1 (0.36) | TRPA1SMN1; SMN2LMNAKDM4E | |
| SCHEMBL21363491 | 0.69 | TRPA1 (0.44) | TRPA1SMN1; SMN2LMNAHTTRAB9A | |
| SCHEMBL22477644 | 0.67 | ADORA2A (0.39) | TRPA1LMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284179-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885SMN1; SMN2 1161/4885LMNA 3183/4885 |
| US-10710994-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, TRPV3 | TRPA1 1/4885SMN1; SMN2 1161/4885LMNA 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.